Statute Details
- Title: Medicines (Good Manufacturing Practice Certificate) Regulations
- Act Code: MA1975-RG16
- Legislative Type: Subsidiary legislation (SL)
- Authorising Act: Medicines Act (Chapter 176), Section 74
- Citation: G.N. No. S 130/2002 (Revised Edition 2004)
- Current version status: Current version as at 27 Mar 2026
- Key provisions (from extract): Section 2 (definitions); Section 3 (application and issuance); Section 4 (fees)
- Commencement: Not specified in the provided extract (historical commencement includes 1 Jun 2002 for the original instrument)
- Most recent fee amendment (from extract): S 491/2024 (effective 1 Jul 2024)
What Is This Legislation About?
The Medicines (Good Manufacturing Practice Certificate) Regulations (“GMP Certificate Regulations”) provide the procedural and financial framework for obtaining a Good Manufacturing Practice Certificate (“GMP Certificate”) in Singapore. In practical terms, the Regulations sit alongside the Medicines Act by operationalising how manufacturers (and manufacturers of active pharmaceutical ingredients) apply for certification that their manufacturing processes meet an approved Good Manufacturing Practice (“GMP”) Standard.
Good Manufacturing Practice is a regulatory concept used internationally to ensure that medicinal products and active pharmaceutical ingredients are consistently produced and controlled to quality standards appropriate to their intended use. The Singapore framework recognises that GMP is not merely a one-off compliance exercise; it requires ongoing conformity, which is reflected in the Regulations’ provisions on assessment, issuance, and certificate validity periods.
The scope of the Regulations is therefore narrow but important: they do not set out the full GMP requirements themselves. Instead, they define what a GMP Certificate is, what GMP Standard is recognised, how applications are made and assessed, how long certificates last, and what fees are payable. For practitioners, this means the Regulations are central to the “certification mechanics” that often determine timelines, costs, and compliance strategy for regulated manufacturers.
What Are the Key Provisions?
1. Definitions and the regulatory “building blocks” (Section 2)
Section 2 defines three core terms that drive the entire regulatory scheme:
- “Active pharmaceutical ingredient”: any raw material used as an active ingredient in the manufacture of a medicinal product. This definition matters because the GMP Certificate regime applies not only to finished medicinal products but also to upstream ingredient manufacturers.
- “Good Manufacturing Practice Certificate”: a certificate relating to the manufacture of a medicinal product or active pharmaceutical ingredient attesting to conformity with a GMP Standard. The emphasis on “attesting to its conformity” indicates that the certificate is evidence of assessed compliance.
- “Good Manufacturing Practice Standard”: the Pharmaceutical Inspection Convention/Pharmaceutical Inspection Co-Operation Scheme (PIC/S) Guide to GMP for medicinal products or active pharmaceutical ingredients (as the case may be), or such other GMP standard approved by the licensing authority. This is a key legal hook: it anchors Singapore’s GMP expectations to an internationally recognised standard, while preserving flexibility for the licensing authority to approve other standards.
2. Application process and issuance (Section 3)
Section 3 is the operational heart of the Regulations. It links the application for a GMP Certificate to section 22 of the Medicines Act (as stated in Section 3(1)).
Section 3(1): Form and manner requires that an application be made to the licensing authority in the form and manner the licensing authority may require. From a practitioner’s perspective, this is a procedural provision with real consequences: compliance with the licensing authority’s prescribed application format, supporting documents, and submission requirements is often a prerequisite to a valid application. While the extract does not list the form, the legal effect is that the licensing authority can set detailed administrative requirements.
Section 3(2): Assessment and issuance provides that upon receipt of an application, the licensing authority may issue a GMP Certificate to the manufacturer, subject to such terms and conditions as the licensing authority thinks fit. The issuance is conditional on “assessment of satisfactory conformity with a Good Manufacturing Practice Standard.” This wording confirms that the certificate is not automatic; it depends on an assessment outcome.
The “terms and conditions” language is particularly important for legal risk management. It means the licensing authority can attach conditions beyond the general GMP Standard—potentially including reporting obligations, limitations, or other compliance requirements. Practitioners should therefore treat the certificate terms as part of the regulatory instrument that must be reviewed, negotiated where possible, and complied with in ongoing operations.
Section 3(3): Validity periods sets out how long a GMP Certificate remains valid. The Regulations distinguish between certificates issued before and after 1 February 2013:
- If issued before 1 February 2013: valid for a period not exceeding 2 years from the date of the certificate.
- If issued on or after 1 February 2013: valid for a period not exceeding 3 years from the date the assessment referred to in Section 3(2) is completed.
Two practical points follow. First, for post-2013 certificates, the validity is tied to the completion date of the assessment, not necessarily the certificate issuance date. Second, the “not exceeding” phrasing indicates that the licensing authority may set a shorter validity period in a given case. For compliance planning, counsel should therefore confirm the exact expiry date and the basis for it, especially where renewal or re-assessment timing affects manufacturing continuity.
3. Fees and no-refund rule (Section 4)
Section 4 sets the fee schedule for GMP Certificates. It provides:
- On application: $6,570.
- For each additional GMP Certificate that does not require further assessment of conformity with any GMP Standard: $220.
The structure suggests that the licensing authority charges a substantial fee for the initial application (likely reflecting assessment costs), while a lower incremental fee applies where additional certificates can be issued without further assessment. For manufacturers operating multiple sites, product lines, or categories, this distinction can materially affect cost modelling and submission strategy.
Section 4(2) states: “No refund shall be made in respect of any fee paid” under paragraph (1). This is a strict provision. Practitioners should advise clients that fee payment is non-recoverable even if the application is unsuccessful or if the certificate is not issued. Accordingly, it is prudent to conduct internal pre-assessment readiness reviews before filing, to reduce the risk of wasted fees and delays.
How Is This Legislation Structured?
The GMP Certificate Regulations are concise and structured around four provisions:
- Section 1 (Citation): provides the short title.
- Section 2 (Definitions): defines “active pharmaceutical ingredient,” “GMP Certificate,” and “Good Manufacturing Practice Standard.”
- Section 3 (Application for GMP Certificate): sets the application mechanism, licensing authority discretion, assessment-based issuance, and validity periods.
- Section 4 (Fees): establishes the fee amounts for applications and additional certificates, and includes a no-refund rule.
Notably, the extract does not show additional parts or detailed GMP operational requirements. Those substantive GMP requirements are instead incorporated by reference through the definition of the “Good Manufacturing Practice Standard” (PIC/S Guide or other approved standards). This drafting approach is common in regulatory systems: the Regulations provide the certification framework, while the GMP standards themselves are referenced rather than reproduced.
Who Does This Legislation Apply To?
The Regulations apply to manufacturers seeking a GMP Certificate for the manufacture of either:
- medicinal products, or
- active pharmaceutical ingredients.
Because “active pharmaceutical ingredient” is defined broadly as any raw material used as an active ingredient, the regime can capture a wide range of upstream suppliers and contract manufacturing arrangements where the entity manufactures APIs for medicinal products.
In addition, the Regulations apply in the context of the Medicines Act’s certification framework (explicitly referenced in Section 3(1) as being “for the purposes of section 22 of the Act”). While the extract does not reproduce section 22, practitioners should read the Regulations together with the Medicines Act provisions governing GMP certification and any downstream licensing or regulatory consequences of holding (or failing to hold) a GMP Certificate.
Why Is This Legislation Important?
Although the GMP Certificate Regulations are short, they are operationally significant for regulated industry participants. A GMP Certificate is often a gating requirement for market access, licensing, supply chain approvals, and regulatory confidence. The Regulations therefore affect not only compliance status but also commercial timelines and contractual arrangements with distributors, wholesalers, and contract manufacturers.
From an enforcement and compliance perspective, the Regulations confirm that certification is based on an assessment of satisfactory conformity with an approved GMP Standard. This means that compliance is evaluated against an external benchmark (PIC/S Guide or other approved standards), and the licensing authority retains discretion to issue certificates subject to terms and conditions. Practitioners should therefore treat GMP certification as a continuing compliance relationship rather than a one-time document.
Finally, the fee provisions and no-refund rule have practical consequences for legal and regulatory strategy. The fee schedule differentiates between an initial assessment and additional certificates that do not require further assessment. Counsel advising on multi-site or multi-category manufacturing should consider whether the “additional certificate” pathway is available and how to structure applications to avoid unnecessary assessment triggers. At the same time, the no-refund rule underscores the importance of readiness and documentation quality before submission.
Related Legislation
- Medicines Act (Chapter 176) — in particular, section 22 (referenced in Section 3(1) of these Regulations) and section 74 (authorising provision for subsidiary legislation)
- PIC/S Guide to Good Manufacturing Practice for Medicinal Products and Active Pharmaceutical Ingredients — incorporated by reference through the definition of “Good Manufacturing Practice Standard” in Section 2
Source Documents
This article provides an overview of the Medicines (Good Manufacturing Practice Certificate) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.